Halozyme Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference

  Halozyme Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare

PR Newswire

SAN DIEGO, Jan. 3, 2013

SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:
HALO) will be presenting at the 31^st Annual J.P. Morgan Healthcare Conference
in San Francisco on Thursday, January 10, 2013 at 10:00 a.m. PT / 1:00 p.m.
ET. Gregory I. Frost, President and Chief Executive Officer of Halozyme
Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's
corporate website at www.halozyme.com, and a recording will be made available
for 90 days following the event. To access the live webcast, please log on to
Halozyme's website approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, that increase the absorption and dispersion of biologics.
Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology
and dermatology that have significant unmet medical need. The Company markets
HYLENEX^® recombinant (hyaluronidase human injection) and has partnerships
with Roche, Baxter, ViroPharma, Intrexon and Pfizer. Halozyme is headquartered
in San Diego, CA. For more information on how we are innovating, please visit
our corporate website at www.halozyme.com.

Media/Investor Contact:
Kurt Gustafson
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com
Press spacebar to pause and continue. Press esc to stop.